BTG, a specialist healthcare company, has reported that its VANISH-1 and VANISH-2 studies have 'demonstrated efficacy in achieving a clinically meaningful improvement' in the appearance of the legs of patients with varicose veins.
The studies found that 80% of patients treated with either the 0.5% or 1.0% dose concentrations reported a much or moderate improvement of symptoms.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Dr Kenneth Todd, a Principal Investigator for VANISH-2 said: "Current treatments for patients with medically-important, symptomatic varicose veins are time-consuming for both patients and physicians and do not offer a comprehensive treatment.
"The publication of the full results for VANISH-1 and VANISH-2 confirm the top-line results already reported and demonstrate that the product, if approved, could offer an effective, comprehensive treatment option for patients with symptomatic varicose veins."
NR
-
Reeves urged to axe stamp duty from UK shares held in an ISAChancellor Rachel Reeves is reportedly considering axing stamp duty from UK shares held in stocks and shares ISAs. What could it mean for your portfolio?
-
Family investment companies explained: how the ultra wealthy shield their money from the taxmanWealthy families are increasingly turning to family investment companies to keep more of their money away from HMRC – but what are these arrangements and how do they work?
